Although further functional studies are need to clarify the direct influence of these abnormal CD4+ T cells on platelet production and destruction, strategies to restore the balance of BM CD4+ T-cell subsets might provide therapeutic benefits for ITP patients. This evidence concerns the gene CD4 and autoimmune thrombocytopenic purpura.